Entering text into the input field will update the search result below

Ebola vaccine faces questions

Apr. 25, 2017 3:54 AM ETMerck & Co., Inc. (MRK) StockMRK, LUMOBy: Yoel Minkoff, SA News Editor3 Comments
  • In December, a vaccine from Merck (NYSE:MRK) and NewLink Genetics (NASDAQ:NLNK) was declared to be 100% effective at preventing people from contracting Ebola, but there are questions about that claim.
  • Scientists from the esteemed U.S. National Academy of Medicine have challenged the methodology of the drugmakers, concluding their vaccine "most likely provides some protection to recipients" but that protection "could in reality be quite low."

Recommended For You

About MRK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRK--
Merck & Co., Inc.